Biotechnology company Amgen on Wednesday provided a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, previously known as AMG 133), emphasizing that there is no observed link between MariTide administration and changes in bone mineral density.

The company reiterated that the Phase 1 study results show no bone safety concerns, maintaining confidence in MariTide's potential.

Amgen anticipates sharing the topline results from the Phase 2 study later in the year.

The company's investment in research and development has resulted in a robust pipeline that builds on it existing portfolio of medicines to treat cancer, heart disease, osteoporosis inflammatory diseases and rare diseases.